Page 2 - Metacrine News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Metacrine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Metacrine Today - Breaking & Trending Today
Zacks Investment Research cut shares of Metacrine (NASDAQ:MTCR – Get Rating) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The […] ....
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 808,600 shares, a drop of 33.7% from the April 15th total of 1,220,000 shares. Based on an average trading volume of 1,730,000 shares, the short-interest […] ....
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 44,748 shares of the company’s stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $0.50, for a total value of $22,374.00. Following the completion of the sale, the chief executive officer now owns 922,510 shares of the […] ....
Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 465,600 shares, a decrease of 20.9% from the February 13th total of 588,600 shares. Based on an average daily volume of 3,470,000 shares, the short-interest ratio is presently […] ....